Reign In Your Distributors And Reps, Chinese Regulator Cautions
Executive Summary
Manufacturers beware, the rollout of a new receipts system could impact how drugs are distributed and sold to public hospitals in China over the course of the new year.
You may also be interested in...
2017 Preview: Fresh Concerns And New Hopes In China
If 2016's Year of the Monkey was a period of ups and downs in China, filled with a series of rapid changes in regulations and plans for overseas expansion by domestic pharma companies, 2017's Year of the Rooster is likely to be even more uncertain, industry insiders say.
2017 Preview: Fresh Concerns And New Hopes In China
If 2016's Year of the Monkey was a period of ups and downs in China, filled with a series of rapid changes in regulations and plans for overseas expansion by domestic pharma companies, 2017's Year of the Rooster is likely to be even more uncertain, industry insiders say.
The ‘Sanming Model’: Bad Omen Or Hope For Pharma In China?
Pharma executives in China may soon get an earful of the name Sanming, as the populist healthcare reform model that began at the small city in Fujian is rolled out nationwide and impacts profoundly how drugs are tendered, priced and distributed.